Davangere Devanand

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Int J Alzheimers Dis 2012:483469. 2012
  2. pmc Relapse risk after discontinuation of risperidone in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA
    N Engl J Med 367:1497-507. 2012
  3. pmc MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Neuroimage 60:1622-9. 2012
  4. pmc The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Am J Geriatr Psychiatry 20:362-73. 2012
  5. ncbi request reprint An open treatment trial of venlafaxine for elderly patients with dysthymic disorder
    D P Devanand
    Late Life Depression Clinic and the Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    J Geriatr Psychiatry Neurol 17:219-24. 2004
  6. ncbi request reprint Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder
    D P Devanand
    Late Life Depression Clinic, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Am J Geriatr Psychiatry 13:59-68. 2005
  7. ncbi request reprint Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Neurol 62:975-80. 2005
  8. ncbi request reprint PET network abnormalities and cognitive decline in patients with mild cognitive impairment
    Davangere P Devanand
    Department of Biological Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:1327-34. 2006
  9. ncbi request reprint Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Neurology 68:828-36. 2007
  10. pmc Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
    Davangere P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Biol Psychiatry 64:871-9. 2008

Research Grants

  1. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere P Devanand; Fiscal Year: 2010
  2. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2005
  3. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2006
  4. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2006
  5. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2007
  6. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2007
  7. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2009
  8. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2004
  9. TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE
    Davangere Devanand; Fiscal Year: 1999
  10. TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE
    Davangere Devanand; Fiscal Year: 2000

Detail Information

Publications42

  1. pmc A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Int J Alzheimers Dis 2012:483469. 2012
    ..The predictor models showed similar differences from each other in both studies, supporting independent validation. MRI hippocampal and entorhinal cortex volumes showed limited added predictive utility to memory and function measures...
  2. pmc Relapse risk after discontinuation of risperidone in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA
    N Engl J Med 367:1497-507. 2012
    ..Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established...
  3. pmc MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Neuroimage 60:1622-9. 2012
    ..Using MRI surface morphometry mapping, to evaluate local deformations of the hippocampus, parahippocampal gyrus, and entorhinal cortex in predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD)...
  4. pmc The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Am J Geriatr Psychiatry 20:362-73. 2012
    ..Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks...
  5. ncbi request reprint An open treatment trial of venlafaxine for elderly patients with dysthymic disorder
    D P Devanand
    Late Life Depression Clinic and the Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    J Geriatr Psychiatry Neurol 17:219-24. 2004
    ..These results indicate that in elderly patients with DD, placebo-controlled trials of a dual reuptake inhibitor such as venlafaxine would be needed to assess its efficacy or to compare its efficacy to that of other antidepressants...
  6. ncbi request reprint Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder
    D P Devanand
    Late Life Depression Clinic, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Am J Geriatr Psychiatry 13:59-68. 2005
    ..The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder...
  7. ncbi request reprint Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Neurol 62:975-80. 2005
    ..In cognitively impaired patients without dementia, the utility of apolipoprotein E (APOE) genotyping is unclear...
  8. ncbi request reprint PET network abnormalities and cognitive decline in patients with mild cognitive impairment
    Davangere P Devanand
    Department of Biological Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:1327-34. 2006
    ..Independent replication in larger samples is needed before clinical application can be considered...
  9. ncbi request reprint Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Neurology 68:828-36. 2007
    ..To evaluate the utility of MRI hippocampal and entorhinal cortex atrophy in predicting conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD)...
  10. pmc Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
    Davangere P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Biol Psychiatry 64:871-9. 2008
    ..The utility of combining early markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's Disease (AD) remains uncertain...
  11. pmc Olfactory identification deficits and MCI in a multi-ethnic elderly community sample
    D P Devanand
    Division of Geriatric Psychiatry, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Neurobiol Aging 31:1593-600. 2010
    ..These findings indicate that the predictive utility of olfactory identification deficits for decline from no MCI to MCI and AD needs to be assessed in longitudinal studies of elderly community samples...
  12. pmc Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls
    D P Devanand
    Division of Geriatric Psychiatry, Columbia University, New York, USA
    J Geriatr Psychiatry Neurol 23:185-98. 2010
    ..These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies...
  13. pmc (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease
    D P Devanand
    NYSPI, Columbia University, New York, NY 10032, USA
    Am J Geriatr Psychiatry 18:959-72. 2010
    ..To examine the utility of single-photon emission computed tomography (SPECT) to predict conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD)...
  14. pmc Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment
    D P Devanand
    Divisions of Geriatric Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neurology 77:125-31. 2011
    ..To evaluate the relations between PET Pittsburgh compound B (PiB-PET) binding (amyloid imaging) and plasma Aβ in patients with mild cognitive impairment (MCI) and similarly aged controls...
  15. pmc A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Int J Geriatr Psychiatry 26:937-43. 2011
    ..In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation...
  16. ncbi request reprint Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients
    D P Devanand
    Late Life Depression Clinic, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    J Affect Disord 78:259-67. 2004
    ....
  17. ncbi request reprint The interrelations between psychosis, behavioral disturbance, and depression in Alzheimer disease
    D P Devanand
    College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Alzheimer Dis Assoc Disord 13:S3-8. 1999
    ..There was no association between depressive features and either cognitive or functional impairment. These results have important implications for the optimal treatment of the psychopathological symptoms of AD...
  18. ncbi request reprint Sertraline treatment of elderly patients with depression and cognitive impairment
    D P Devanand
    Late Life Depression Clinic, Memory Disorders Center, Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 26, New York, NY 10032, USA
    Int J Geriatr Psychiatry 18:123-30. 2003
    ....
  19. pmc Disruptive behavior as a predictor in Alzheimer disease
    Nikolaos Scarmeas
    Gertrude H Sergievsky Center, Columbia University Medical Center, New York, NY 10032, USA
    Arch Neurol 64:1755-61. 2007
    ..Disruptive behavior is common in Alzheimer disease (AD). There are conflicting reports regarding its ability to predict cognitive decline, functional decline, institutionalization, and mortality...
  20. pmc Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease
    Arthur Mikhno
    Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York, USA
    J Nucl Med 49:1262-9. 2008
    ..We assessed the use of data-determined standardized voxels of interest (VOIs) to improve the classification capability of 11C-PIB scans on patients with AD...
  21. pmc Delusions and hallucinations are associated with worse outcome in Alzheimer disease
    Nikolaos Scarmeas
    Cognitive Neuroscience Division of the Taub Institute for Research on Alzheimer s Disease and the Aging Brain, The Gertrude H Sergievsky Center, New York, NY 10032, USA
    Arch Neurol 62:1601-8. 2005
    ..According to all previous literature, they are not associated with mortality...
  22. pmc Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease
    N Scarmeas
    Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer s Disease and the Aging Brain, New York, NY, USA
    Neurology 58:1182-8. 2002
    ..Previous studies investigating the association between APOE genotype and psychiatric symptomatology in AD have reported contradictory results...
  23. ncbi request reprint Functional deficits in patients with mild cognitive impairment: prediction of AD
    M H Tabert
    Memory Disorders Clinic and Department of Biological Psychiatry, New York State Psychiatric Institute, Taub Alzheimer s Disease Research Center, USA
    Neurology 58:758-64. 2002
    ..To evaluate the predictive utility of self-reported and informant-reported functional deficits in patients with mild cognitive impairment (MCI) for the follow-up diagnosis of probable AD...
  24. ncbi request reprint ECT in bipolar and unipolar depression: differences in speed of response
    J J Daly
    Department of Biological Psychiatry, New York State Psychiatric Institute, NY 10032, USA
    Bipolar Disord 3:95-104. 2001
    ..We contrasted a large sample of bipolar (BP) and unipolar (UP) depressed patients in likelihood and rapidity of clinical improvement with ECT...
  25. pmc Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
    Gregory H Pelton
    Late Life Depression Clinic, The Memory Disorders Center, and The Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA
    Int J Geriatr Psychiatry 23:670-6. 2008
    ..To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment...
  26. ncbi request reprint Psychopathological features in Alzheimer's disease: course and relationship with cognitive status
    Roee Holtzer
    Sergievsky Center, New York, New York 10032, USA
    J Am Geriatr Soc 51:953-60. 2003
    ..To examine the course, clinical correlates, and relationship between cognitive status and psychopathological features in patients with probable Alzheimer's disease (AD) followed over a 5-year period...
  27. ncbi request reprint The effects of electroconvulsive therapy on memory of autobiographical and public events
    S H Lisanby
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York 10032, USA
    Arch Gen Psychiatry 57:581-90. 2000
    ..This study examined the short- and long-term effects of differing forms of ECT on memory of personal and impersonal (public) events...
  28. ncbi request reprint A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities
    H A Sackeim
    Department of Biological Psychiatry, New York State Psychiatric Institute, NY 10032, USA
    Arch Gen Psychiatry 57:425-34. 2000
    ..While RUL ECT results in less severe short-term and long-term cognitive effects, there is concern that it is less efficacious than BL ECT...
  29. ncbi request reprint Olfactory dysfunction as a predictor of neurodegenerative disease
    Mark W Albers
    Department of Neurology, Columbia UniversityCollege of Physicians and Surgeons, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 6:379-86. 2006
    ....
  30. ncbi request reprint Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment
    Matthias H Tabert
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 126, New York, NY 10032, USA
    Arch Gen Psychiatry 63:916-24. 2006
    ..The likelihood of conversion to Alzheimer disease (AD) in mild cognitive impairment (MCI) and the "optimal" early markers of conversion need to be established...
  31. ncbi request reprint Functional significance of mild cognitive impairment in elderly patients without a dementia diagnosis
    S M Albert
    Gertrude H Sergievsky Center, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Am J Geriatr Psychiatry 7:213-20. 1999
    ..Informants' reports or standardized performance-based assessment should be considered in the clinical evaluation of such patients...
  32. ncbi request reprint A 10-item smell identification scale related to risk for Alzheimer's disease
    Matthias H Tabert
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY, USA
    Ann Neurol 58:155-60. 2005
    ..Independent replication is needed to validate these findings...
  33. ncbi request reprint Low testosterone levels in elderly men with dysthymic disorder
    Stuart N Seidman
    Late Life Depression Clinic, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 159:456-9. 2002
    ..Symptoms of both HPG axis hypofunction and dysthymic disorder include dysphoria, fatigue, and low libido. The authors compared total testosterone levels in three groups of elderly men...
  34. ncbi request reprint Adverse life events in elderly patients with major depression or dysthymic disorder and in healthy-control subjects
    D P Devanand
    Late Life Depression Clinic and the Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York 10032, USA
    Am J Geriatr Psychiatry 10:265-74. 2002
    ..The subjective impact of adverse life events may play an important role in the expression of depressive illness in elderly patients, particularly in major depression, and it needs to be considered in clinical management...
  35. ncbi request reprint Comorbid psychiatric disorders in late life depression
    D P Devanand
    Late Life Depression Clinic and the Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York 10032, USA
    Biol Psychiatry 52:236-42. 2002
    ..Since comorbid psychiatric disorders affect clinical course and prognosis, and may worsen long-term disability in late life depression, considerably more research in this field is needed...
  36. ncbi request reprint Gabapentin in geriatric mania
    M Awais Sethi
    Columbia University Binghamton Psychiatric Center geriatric psychiatry fellowship program, Arden Hill Hospital, and Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia Univ, NY, USA
    J Geriatr Psychiatry Neurol 16:117-20. 2003
    ..This case series suggests that controlled studies are warranted to examine gabapentin's efficacy and side effects, particularly as an adjunctive medication, in geriatric mania...
  37. ncbi request reprint Focal prefrontal seizures induced by bilateral ECT
    L S Boylan
    Department of Neurology, New York University School of Medicine, New York, New York, USA
    J ECT 17:175-9. 2001
    ..These events were more likely to occur later in the course of treatment. DISCUSSION: We suggest that BL ECT may induce focal seizures in prefrontal areas and that these seizures are more likely to occur later in the treatment course...
  38. ncbi request reprint Pica in the geriatric mentally ill: unrelenting and potentially fatal
    Noel I Dumaguing
    Columbia University Binghamton Psychiatric Center, Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, New York, USA
    J Geriatr Psychiatry Neurol 16:189-91. 2003
    ..When pica occurs in elderly patients with mental illness, the risk of mortality should be taken into account in clinical management...
  39. ncbi request reprint Validation and optimization of statistical approaches for modeling odorant-induced fMRI signal changes in olfactory-related brain areas
    Matthias H Tabert
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
    Neuroimage 34:1375-90. 2007
    ....
  40. pmc Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance
    Nikolaos Scarmeas
    Cognitive Neuroscience Division of the Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Neuroimage 23:35-45. 2004
    ..Expression of covariance patterns correlates with cognitive and functional performance measures, holding promise for meaningful associations with underlying biopathological processes...
  41. pmc Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele)
    Nikolaos Scarmeas
    Departments of Neurology, College of Physicians and Surgeons of Columbia University Medical Center 622 West 168th St, PH 19th floor New York, NY 10032, USA
    Am J Geriatr Psychiatry 12:596-605. 2004
    ..The authors investigated APOE-mediated differential brain activation in a group of healthy elderly subjects...
  42. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:125-8. 2002
    ....

Research Grants20

  1. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere P Devanand; Fiscal Year: 2010
    ..Accurate prediction of MCI conversion to AD will help identify patients who need early treatment, facilitate patient/family planning for their own future, and improve patient selection for clinical trials. ..
  2. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2005
    ..The results will be of considerable value to the practicing clinician and have substantial implications for the regulatory oversight of elder care. ..
  3. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2006
    ..The results will be of considerable value to the practicing clinician and have substantial implications for the regulatory oversight of elder care. ..
  4. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2006
    ..This study will lead to improved clinical accuracy for the early diagnosis of AD, and will eventually help enrich high-risk patient selection for clinical trials of therapeutic agents in MCI. ..
  5. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2007
    ..Accurate prediction of MCI conversion to AD will help identify patients who need early treatment, facilitate patient/family planning for their own future, and improve patient selection for clinical trials. ..
  6. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2007
    ..The results will be of considerable value to the practicing clinician and have substantial implications for the regulatory oversight of elder care. ..
  7. QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME
    Davangere Devanand; Fiscal Year: 2009
    ..Accurate prediction of MCI conversion to AD will help identify patients who need early treatment, facilitate patient/family planning for their own future, and improve patient selection for clinical trials. ..
  8. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2004
    ..The results will be of considerable value to the practicing clinician and have substantial implications for the regulatory oversight of elder care. ..
  9. TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE
    Davangere Devanand; Fiscal Year: 1999
    ..These clinical data will be important in improving the management of AD patients with behavioral complications. ..
  10. TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE
    Davangere Devanand; Fiscal Year: 2000
    ..These clinical data will be important in improving the management of AD patients with behavioral complications. ..
  11. TREATMENT OF BEHAVIORAL SYMPTOMS IN ALZHEIMERS DISEASE
    Davangere Devanand; Fiscal Year: 2001
    ..These clinical data will be important in improving the management of AD patients with behavioral complications. ..
  12. Antipsychotic Discontinuation in Alzheimer s Disease
    Davangere Devanand; Fiscal Year: 2003
    ..The results will be of considerable value to the practicing clinician and have substantial implications for the regulatory oversight of elder care. ..